REGN
Premium GrowerAI screen passRegeneron Pharmaceuticals, Inc. · Healthcare · United States · $82.9B cap · $822.2M/day traded
$951.19 -0.9% · close 12 Nov · scored 13 Nov
Premium Grower: Strong business with the market behind it, priced at a premium.
As of 13 Nov 2026, the MoatMap Score for Regeneron Pharmaceuticals, Inc. (REGN) is 93/100, ranked against 25,000+ stocks in 38 markets (Quality 71, Value 45, Momentum 83, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
Regeneron clears the calibrated bar. All three legs are above the floor (Q69 V52 M52) and a buyback retiring 2.43% of shares provides substantial corroboration. Nothing adverse survives the evidence test: the only insider figure rounds to 0.00%, treated as unusable rather than adverse, and there is no negative earnings revision. Quality at Q69 is the strongest part of the case.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT REGENERON PHARMACEUTICALS, INC.
Read
Regeneron Pharmaceuticals, Inc. is a leading biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines for serious diseases, with a strong presence in areas like eye diseases, allergic/inflammatory conditions, and oncology. The company's proprietary VelocImmune antibody discovery platform and robust R&D capabilities enable the creation of blockbuster biologic drugs, establishing a significant competitive moat through intellectual property and scientific leadership. Regeneron's integrated approach from research to commercialization underpins its success.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.2B | 13.1B | 14.2B | 14.3B | 5.6% | 16.9B | 18.8B | 20.2B | 18.5% |
| EPS | 40.51 | 37.05 | 40.90 | 43.07 | 2.1% | 45.24 | 66.83 | 70.04 | 27.5% |
| Shares | 109.6M | 109.4M | 109.6M | 105.7M | -3.5% | 101.6M | — | — | — |
| Debt | 2.7B | 2.7B | 2.7B | 2.7B | 0.1% | 2.7B | — | — | — |
| Equity | 22.7B | 26.0B | 29.4B | 31.3B | 11.3% | — | — | — | — |
| Op CF | 5.0B | 4.6B | 4.4B | 5.0B | -0.2% | 4.8B | — | — | — |
| Inv CF | -3.8B | -3.2B | -2.5B | -629.1M | — | — | — | — | — |
| Fin CF | -1.0B | -1.8B | -2.2B | -3.7B | — | — | — | — | — |
Above its 200-day average and 4% below its 52-week high.
Calmer than 65% of stocks we rank over the past year (volatility 34% a year).
How this is worked out
The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.
- Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
- Finding a floor: It fell hard, but has set no new low for more than two weeks.
- Turning up: It has climbed off its low and is back above a rising 50-day average.
- In an uptrend (this stock): It is near its 52-week high and above its 200-day average.
- No clear trend: None of the above: no recent deep fall and no steady climb.
- No read yet: Not enough price history yet: it needs a year of trading.
In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.
The exact rules
Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of REGN are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc.(you) | $82.9B | 93 |
| UCB.BR | UCB SA | $58.3B | 86 |
| ONC | BeOne Medicines AG | $43.0B | 89 |
| ARGX.BR | argenx SE | $55.1B | 74 |
| CSL.AX | CSL Limited | $66.4B | 65 |
| INCY | Incyte Corporation | $23.5B | 85 |
| EXEL | Exelixis, Inc. | $16.0B | 96 |
| 2269.HK | WuXi Biologics (Cayman) Inc. | $24.0B | 81 |
| HALO | Halozyme Therapeutics, Inc. | $14.3B | 90 |
| 1177.HK | Sino Biopharmaceutical Limited | $11.3B | 93 |
Peer medians: ROE 3.0% · P/E 23.0x · Gross margin 53.2%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.